A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-27. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The statement noted: "We cannot celebrate the birthday of a state founded on terrorism, massacres and the dispossession of another people from their land.", "We will celebrate when Arab and Jew live as equals in a peaceful Middle East" Jack Rosenthal (8 September 1931 – 29 May 2004) was an English playwright. He wrote 129 early episodes of the ITV soap opera Coronation Street and over 150 screenplays, including original TV plays, feature films, and adaptations. Jolyon Rubinstein (born 22 April 1981), actor, writer, producer, scriptwriter, journalist, op-ed columnist and director; best known for scriptwriting and performing in The Revolution Will Be Televised, a show on BBC Three, alongside Heydon Prowse; Rubinstein's first professional acting job was that of the PR in the TV series Nathan Barley; co-wrote script and acted in BBC Three television show The Revolution Will Be Televised; also wrote for the Financial Times Business and Yahoo In 2018, he co-created the ITV2 hip hop comedy show Don't Hate the Playaz. In 2020, Rubinstein launched the satire news show Not The News with Jolyon Rubinstein David Seidler (born 1937) playwright and film and television writer. best known for writing the scripts for the stage version and screen version for the story The King's Speech for which he won the Academy Award and a BAFTA for Best Original Screenplay; son of Doris Seidler (1912–2010), painter, printmaker and graphic artist. Peter and Anthony Shaffer, playwrights Gary Sinyor (born Manchester, England, 1962), film director, playwright, producer, and writer.
patient's age obesity presence of infection poor nutrition or hydration prescribed medication substance abuse and smoking general effect of the wound on a patient's lifestyle (pain, wound odor, excessive drainage)
== Packaging == Frozen food packaging must maintain its integrity throughout filling, sealing, freezing, storage, transportation, thawing, and often cooking. As many frozen foods are cooked in a microwave oven, manufacturers have developed packaging that can go directly from freezer to the microwave. In 1974, the first differential heating container (DHC) was sold to the public. A DHC is a sleeve of metal designed to allow frozen foods to receive the correct amount of heat. Various sized apertures were positioned around the sleeve. The consumer would put the frozen dinner into the sleeve according to what needed the most heat. This ensured proper cooking. Today there are multiple options for packaging frozen foods. Boxes, cartons, bags, pouches, boil-in-bags, lidded trays and pans, crystallized PET trays, and composite and plastic cans. Scientists continue to research new aspects of frozen food packaging. Active packaging offers many new technologies that can actively sense and then neutralize the presence of bacteria or other harmful species. Active packaging can extend shelf-life, maintain product safety, and help preserve the food over a longer period of time. Several functions of active packaging are being researched:
=== Drug discovery problems === In September 2005, Dr. Reddy's spun off its drug discovery and research wing into a separate company called Perlecan Pharma Private Limited. At the time, this was hailed as an innovative move, but in 2008, the company had to be wound down due to funding constraints. Dr. Reddy's was the first Indian pharma company to attempt such an effort to de-couple risk of drug discovery from the parent company by creating a separate company with an external source of funding. Perlecan Pharma was partially funded by ICICI Venture Capital and Citigroup Venture International, both of which held a 43% stake in Perlecan for an estimated $22.5 million. However, the company was forced to buy back the Perlecan shares from ICICI and Citigroup due to doubts regarding the commercial viability of the drug candidates that were in Perlecan's pipeline. At that point, Perlecan became a wholly owned subsidiary. In the board meeting of 23 October 2008, the company chose to amalgamate/absorb Perlecan, thereby making it an in-house research facility, as it was before 2005. In 2009, the company did a U-turn and has handed over discovery research and related intellectual property to its Bangalore-based subsidiary, with the possibility of spinning it off as a different entity altogether. "The company may be hoping to find a strategic partner in the future to share the risks and research funding."
Sources: en.wikipedia.org
The Iveagh Markets in Dublin, Ireland was an indoor market that was divided into a dry market that sold clothes and a food market that sold fish, fruit, and vegetables. The market operated from 1906 and had become dilapidated by the 1980s. The last stalls closed in the 1990s and the building is still derelict as of 2018 despite failed attempts to redevelop the site into a new food market complex.
Towards the late 18th century, Mathurin Jacques Brisson (1723–1806) and Comte de Buffon (1707–1788) began new works on birds. Brisson produced a six-volume work Ornithologie in 1760 and Buffon's included nine volumes (volumes 16–24) on birds Histoire naturelle des oiseaux (1770–1785) in his work on science Histoire naturelle générale et particulière (1749–1804). Jacob Temminck sponsored François Le Vaillant [1753–1824] to collect bird specimens in Southern Africa and Le Vaillant's six-volume Histoire naturelle des oiseaux d'Afrique (1796–1808) included many non-African birds. His other bird books produced in collaboration with the artist Barraband are considered among the most valuable illustrated guides ever produced. Louis Pierre Vieillot (1748–1831) spent 10 years studying North American birds and wrote the Histoire naturelle des oiseaux de l'Amerique septentrionale (1807–1808?). Vieillot pioneered in the use of life histories and habits in classification. Alexander Wilson composed a nine-volume work, American Ornithology, published 1808–1814, which is the first such record of North American birds, significantly antedating Audubon. In the early 19th century, Lewis and Clark studied and identified many birds in the western United States. John James Audubon, born in 1785, observed and painted birds in France and later in the Ohio and Mississippi valleys. From 1827 to 1838, Audubon published The Birds of America, which was engraved by Robert Havell Sr. and his son Robert Havell Jr.
People with diabetes can benefit from education about the disease and treatment, dietary changes, and exercise, with the goal of keeping both short-term and long-term blood glucose levels within acceptable bounds. In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications are recommended to control blood pressure. Weight loss can prevent progression from prediabetes to diabetes type 2, decrease the risk of cardiovascular disease, or result in a partial remission in people with diabetes. No single dietary pattern is best for all people with diabetes. Healthy dietary patterns, such as the Mediterranean diet, low-carbohydrate diet, or DASH diet, are often recommended, although evidence does not support one over the others. According to the ADA, "reducing overall carbohydrate intake for individuals with diabetes has demonstrated the most evidence for improving glycemia", and for individuals with type 2 diabetes who cannot meet the glycemic targets or where reducing anti-glycemic medications is a priority, low or very-low carbohydrate diets are a viable approach. For overweight people with type 2 diabetes, any diet that achieves weight loss is effective. A 2020 Cochrane systematic review compared several non-nutritive sweeteners to sugar, placebo and a nutritive low-calorie sweetener (tagatose), but the results were unclear for effects on HbA1C, body weight and adverse events.
Sources: en.wikipedia.org
Click chemistry is an approach to chemical synthesis that is used to join two molecules. The application of the term, click, as a qualifier to the type of chemistry refers to an emphasis on efficiency and simplicity. To link two molecular components, each is first fitted with appropriate functional groups, such as azide and alkyne groups. These components are then "clicked" together in a process that is highly favorable and which tolerates many functional groups that might complicate other coupling processes.
Social resistance to the policies of Marxist–Leninist regimes in Eastern Europe accelerated in strength with the rise of the Solidarity, the first non-Marxist–Leninist controlled trade union in the Warsaw Pact that was formed in the People's Republic of Poland in 1980. In 1985, Mikhail Gorbachev rose to power in the Soviet Union and began policies of radical political reform involving political liberalisation, called perestroika and glasnost. Gorbachev's policies were designed at dismantling authoritarian elements of the state that were developed by Stalin, aiming for a return to a supposed ideal communist state that retained one-party structure while allowing the democratic election of competing candidates within the party for political office. Gorbachev also aimed to seek détente with the West and end the Cold War that was no longer economically sustainable to be pursued by the Soviet Union. The Soviet Union and the United States under President George H. W. Bush joined in pushing for the dismantlement of apartheid and oversaw the dismantlement of South African colonial rule over Namibia.
) of the interaction between two or more molecules in solution. This is achieved by measuring the enthalpies of a series of binding reactions caused by injections of a solution of one molecule to a reaction cell containing a solution of another molecule. The enthalpy values are plotted over the molar ratios resulting from the injections. From the plot, the molar reaction enthalpy
=== Fruit juices, fruit beverages, and sodas === On November 10, 2011, Starbucks acquired juice company Evolution Fresh for US$30 million in cash and planned to start a chain of juice bars starting in around the middle of 2012, venturing into territory staked out by Jamba Inc. Its first store released in San Bernardino, California and plans for a store in San Francisco were to be launched in early 2013. In March 2012, Starbucks began selling a line of iced Starbucks Refresher beverages that contain a green coffee extract. The beverages are fruit flavored and contain caffeine but advertised as having no coffee flavor. Starbucks's green coffee extraction process involves soaking the beans in water. In June 2014, Starbucks began trialing its own line of carbonated sodas, dubbed "Fizzio". The drinks required a special machine to make.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.